407 related articles for article (PubMed ID: 17373187)
21. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
22. Care of patients with psoriasis: an audit of U.K. services in secondary care.
Eedy DJ; Griffiths CE; Chalmers RJ; Ormerod AD; Smith CH; Barker JN; Potter J; Ingham J; Lowe D; Burge S
Br J Dermatol; 2009 Mar; 160(3):557-64. PubMed ID: 19120330
[TBL] [Abstract][Full Text] [Related]
23. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.
Dubertret L; Mrowietz U; Ranki A; van de Kerkhof PC; Chimenti S; Lotti T; Schäfer G;
Br J Dermatol; 2006 Oct; 155(4):729-36. PubMed ID: 16965422
[TBL] [Abstract][Full Text] [Related]
24. Increasing use of more potent treatments for psoriasis.
Strowd LC; Yentzer BA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2009 Mar; 60(3):478-81. PubMed ID: 19058875
[TBL] [Abstract][Full Text] [Related]
25. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis.
Huang W; Cordoro KM; Taylor SL; Feldman SR
J Am Acad Dermatol; 2008 Jun; 58(6):970-7. PubMed ID: 18384909
[TBL] [Abstract][Full Text] [Related]
26. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry.
Nast A; Reytan N; Rosumeck S; Erdmann R; Rzany B
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1337-42. PubMed ID: 18624864
[TBL] [Abstract][Full Text] [Related]
27. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
28. Approach to managing patients with nail psoriasis.
Reich K
J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
[TBL] [Abstract][Full Text] [Related]
30. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
31. Biological therapies in the systemic management of psoriasis: International Consensus Conference.
Sterry W; Barker J; Boehncke WH; Bos JD; Chimenti S; Christophers E; De La Brassinne M; Ferrandiz C; Griffiths C; Katsambas A; Kragballe K; Lynde C; Menter A; Ortonne JP; Papp K; Prinz J; Rzany B; Ronnevig J; Saurat JH; Stahle M; Stengel FM; Van De Kerkhof P; Voorhees J
Br J Dermatol; 2004 Aug; 151 Suppl 69():3-17. PubMed ID: 15265063
[TBL] [Abstract][Full Text] [Related]
32. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
Souliotis K; Golna C; Kani C; Litsa P
J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
[TBL] [Abstract][Full Text] [Related]
33. Biologic therapy with or without topical treatment in psoriasis: what does the current evidence say?
Jensen JD; Delcambre MR; Nguyen G; Sami N
Am J Clin Dermatol; 2014 Oct; 15(5):379-85. PubMed ID: 25027461
[TBL] [Abstract][Full Text] [Related]
34. The role of topical therapy for patients with extensive psoriasis.
Feldman SR; Gelfand JM; Stein Gold L; Jones SD
Cutis; 2007 Jan; 79(1 Suppl 2):18-31. PubMed ID: 17367042
[TBL] [Abstract][Full Text] [Related]
35. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
Reich K; Griffiths CE
Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?
van de Kerkhof PC; Mrowietz U; Segaert S; Kragballe K
Br J Dermatol; 2007 Apr; 156(4):771-2. PubMed ID: 17263798
[No Abstract] [Full Text] [Related]
37. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review.
Christophers E; Griffiths CE; Gaitanis G; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):921-5. PubMed ID: 16922938
[TBL] [Abstract][Full Text] [Related]
38. Biologic therapies for psoriasis.
de Felice C; Ardigo M; Berardesca E
J Rheumatol Suppl; 2009 Aug; 83():62-4. PubMed ID: 19661545
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial.
Prinsen CA; Spuls PI; Lindeboom R; Sprangers MA; de Rie MA; de Korte J
Br J Dermatol; 2015 Oct; 173(4):1091-4. PubMed ID: 25975387
[No Abstract] [Full Text] [Related]
40. Systemic and light therapies for the management of childhood psoriasis: part II.
Cordoro KM
Skin Therapy Lett; 2008 May; 13(4):1-3. PubMed ID: 18648714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
